Position in AZN
as of Mar 31, 2026
· filed Apr 13, 2026
Position Value
$284,897,109
New position
Shares Held
1,444,565
first reported quarter
Ownership
0.093%
of shares outstanding
% of Portfolio
3.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Artemis Investment Management LLP holds $1,107,485,466 across 8 Drug Manufacturers - General names. AZN ranks #1 (25.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
This page
|
1,444,565 | $284,897,109 | |
| 2 | ABBV |
AbbVie Inc.
|
1,041,483 | $226,512,137 | |
| 3 | PFE |
Pfizer Inc
|
7,392,508 | $207,581,624 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
2,885,298 | $174,993,323 | |
| 5 | BIIB |
Biogen Inc.
|
571,571 | $104,786,111 | |
| 6 | LLY |
ELI LILLY & Co
|
92,854 | $85,404,323 | |
| 7 | JNJ |
Johnson & Johnson
|
65,168 | $15,929,665 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
52,961 | $7,381,174 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $284,897,109 | 1,444,565 | Shares | Sole | 2026-04-13 | |
| No filing history on record for this holder in this stock. | ||||||